NeoGenomics (NEO) Set to Announce Quarterly Earnings on Wednesday

NeoGenomics (NASDAQ:NEOGet Rating) is scheduled to be announcing its earnings results before the market opens on Wednesday, April 27th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. NeoGenomics has set its FY 2022 guidance at $-0.650-$-0.530 EPS.Investors interested in listening to the company’s conference call can do so using this link.

NeoGenomics (NASDAQ:NEOGet Rating) last announced its quarterly earnings results on Wednesday, February 23rd. The medical research company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. The company had revenue of $125.73 million during the quarter, compared to analyst estimates of $125.77 million. NeoGenomics had a negative return on equity of 4.17% and a negative net margin of 1.72%. The firm’s revenue was down .2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 earnings per share. On average, analysts expect NeoGenomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ NEO opened at $11.95 on Wednesday. The firm has a market capitalization of $1.48 billion, a P/E ratio of -108.63 and a beta of 0.74. NeoGenomics has a 1-year low of $11.00 and a 1-year high of $54.74. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.81 and a quick ratio of 7.54. The business’s 50-day simple moving average is $16.90 and its 200-day simple moving average is $28.40.

In other NeoGenomics news, CFO William Bonello sold 3,209 shares of NeoGenomics stock in a transaction that occurred on Monday, March 7th. The stock was sold at an average price of $18.29, for a total transaction of $58,692.61. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.70% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its holdings in shares of NeoGenomics by 112.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 507,857 shares of the medical research company’s stock valued at $17,327,000 after acquiring an additional 269,139 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of NeoGenomics in the 4th quarter valued at approximately $281,000. California State Teachers Retirement System increased its holdings in shares of NeoGenomics by 4.9% in the 4th quarter. California State Teachers Retirement System now owns 160,355 shares of the medical research company’s stock valued at $5,471,000 after acquiring an additional 7,421 shares during the last quarter. State of Tennessee Treasury Department increased its holdings in shares of NeoGenomics by 2.7% in the 4th quarter. State of Tennessee Treasury Department now owns 52,625 shares of the medical research company’s stock valued at $1,796,000 after acquiring an additional 1,390 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in shares of NeoGenomics by 0.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 100,198 shares of the medical research company’s stock valued at $3,419,000 after acquiring an additional 925 shares during the last quarter. Institutional investors own 97.04% of the company’s stock.

NEO has been the topic of several research analyst reports. BTIG Research reduced their price objective on NeoGenomics from $35.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, March 29th. Stephens lowered NeoGenomics from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $34.00 to $16.00 in a research note on Tuesday, March 29th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Friday, March 4th. StockNews.com raised NeoGenomics to a “sell” rating in a research note on Saturday. Finally, Craig Hallum reduced their price target on NeoGenomics from $46.00 to $30.00 in a research report on Thursday, February 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $24.64.

NeoGenomics Company Profile (Get Rating)

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.

See Also

Earnings History for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.